-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2022 Annual Meeting of the European Society of Oncology (ESMO) will be held
Abstract number: 1744P
:Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study
Research background
Several ICIs have become the standard of care for patients with aUC who have progressed (platinum resistance) after platinum chemotherapy, and albumin paclitaxel has also been widely used
Research design
The multicenter, one-arm, Phase 2 study included patients who
Research results
As of January 2022, a total of 20 eligible patients were included in the
Conclusions of the study
Preliminary analysis results show that carellizumab combined with albumin paclitaxel has good antitumor activity and safety
Reference source:Wang Mumu
Reviewed: LR
Executive: Wang Mumu